Who is sponsoring NCT04111822?

NCT04111822 is sponsored by Cristina Martinez.

What condition does NCT04111822 study?

NCT04111822 studies Sepsis, Septic Shock.

Is NCT04111822 still recruiting?

NCT04111822 is currently completed. Last updated 6 October 2023.

Last reviewed 2023-10-06 · How we verify

NCT04111822

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Pilot Study on the Use of Hydrocortisone, Vitamin c and Tiamine in Patient With Sepsis and Septic Shock

Completed Phase 3 Last updated 6 October 2023

What this trial tests

Phase 3 trial testing red blood cells transfusion, tranexamic acid (TXA) and fibrinogen concentrate in Sepsis in 40 participants. Completed in 31 October 2020.

Timeline

31 October 2018

Primary endpoint
31 October 2020

31 October 2020

Quick facts

Lead sponsor	Cristina Martinez
Phase	Phase 3
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	40
Start date	31 October 2018
Primary completion	31 October 2020
Estimated completion	31 October 2020
Sites	1 location across Spain

Drugs / interventions tested

red blood cells transfusion, tranexamic acid (TXA) and fibrinogen concentrate — full drug profile →
on crystalloid fluid and Tranexamic acid — full drug profile →

Conditions studied

Sepsis — all drugs for Sepsis →
Septic Shock — all drugs for Septic Shock →

Sponsor

Cristina Martinez — full company profile →

Who can join

18 and older, any sex, with Sepsis or Septic Shock. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Due to the high incidence, mortality and short and long term complications of sepsis and septic shock, it is necessary to look for strategies to try to minimize this impact.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Treating sepsis with vitamin C, thiamine, and hydrocortisone: Exploring the quest for the magic elixir.
Obi J, Pastores SM, Ramanathan LV, Yang J, et al · · 2020 · cited 19× · PMID 32061462 · DOI 10.1016/j.jcrc.2019.12.011

Verify or expand the search:

Other recruiting trials for Sepsis

Currently open trials in the same condition.

NCT07507877 — Infraclavicular Axillary Vein Collapsibility Index as a Predictor of Fluid Responsiveness · recruiting
NCT07154615 — Assessing Immune Dysfunction in Sepsis · recruiting
NCT07419802 — OxiCLEAR (Oxiris Cytokines and Endotoxin Adsorption Rate) Study · recruiting
NCT07351344 — African Survey on Sepsis Knowledge (ASK) · recruiting
NCT07448805 — Accuracy and Safety of the Syai Tag System for Continuous Glucose Monitoring in Intensive Internal Care Unit · NA · recruiting

Other Cristina Martinez trials

Trials by the same sponsor.

NCT04149171 — Transfusion of Red Blood Cells, Tranexamic Acid and Fibrinogen Concentrate for Severe Trauma Hemorrhage · Phase 3 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04111822 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Cristina Martinez
Last refreshed: 6 October 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04111822.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing